NAMPT knockdown diminished the MSC/NAD+‐MSC–dependent decrease in Atrogin 1/MuRF1 levels and the increase in myotube diameter, indicating that NAD+ enhances the therapeutic effect of MSCs on muscle atrophy by promoting NAMPT secretion. The gene discussed is FBXO32; the disease is Atrophy.